Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002756988 | SCV003026497 | likely benign | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004064716 | SCV003541373 | uncertain significance | Cardiovascular phenotype | 2021-06-22 | criteria provided, single submitter | clinical testing | The c.1555G>A (p.G519S) alteration is located in exon 8 (coding exon 8) of the EPHB4 gene. This alteration results from a G to A substitution at nucleotide position 1555, causing the glycine (G) at amino acid position 519 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Clinical Genomics Laboratory, |
RCV005051983 | SCV005685293 | uncertain significance | Capillary malformation-arteriovenous malformation 2 | 2024-07-05 | criteria provided, single submitter | clinical testing | A EPHB4 c.1555G>A (p.Gly519Ser) variant was identified at a heterozygous allelic fraction of 52%, a frequency which may be consistent with germline origin. This variant, to our knowledge, has not been reported in the medical literature and is only observed on 24/1,591,000 alleles in the general population (gnomAD v4.1.0). The variant has been reported in the ClinVar database as a variant of uncertain clinical significance by two submitters (ClinVar Variation ID: 1985154). Computational predictors suggest that this variant does not impact EPHB4 function. Due to limited information, and based on ACMG/AMP guidelines for variant interpretation (Richards S et al., PMID: 25741868), the clinical significance of the EPHB4 c.1555G>A (p.Gly519Ser) variant is uncertain at this time. |